Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine

“…The lowest dose of the vaccine (1/10) performed well and was selected for further clinical studies. Similar results were observed by Bravo and colleagues in a phase 3 trial in the Philippines using the 1/10 dose [6] . Another phase 3, observer-blinded, randomised, and multicentre primary vaccination trial was conducted in Panama with infants vaccinated with three doses of either IPV–Al or standard IPV at 2, 4 and 6 months of age.…”

Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in EPI Schedule of India

“…3-dose IPV schedule at -6, -10 and -14 weeks provided high immunogenicity of ≥90% against all serotypes. Similar findings were reported in trials from Cuba and Philippines with 3 doses of IPV administered at 6, 10 and 14 weeks of age of a child -Cuba trial: minimum of 95% seroconversion rate against types 1 and 3; Philippines trial: 99% seroconversion rates against all three types [26]. Addition of another dose of IPV closed immunity gaps further for all three serotypes.…”

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age

“… 34 Of note, in a recent clinical study in the Philippines in 6-week-old infants, the high seroprotection rate against poliovirus measured before vaccination was not an obstacle to seroconversion in the majority of infants following vaccination with Salk-IPV adjuvanted on aluminum. 35 …”